|
|
 Previous Article | Table of Contents | Next Article 
Long-term follow-up of patients with hairy cell leukemia after treatment
with 2'-deoxycoformycin
EH Kraut, MR Grever and BA Bouroncle
Department of Internal Medicine, Ohio State University, Columbus 43210.
Twenty-four patients with advanced hairy cell leukemia treated with 2'-
deoxycoformycin (dCF) were studied after achieving complete remission to
determine the impact of treatment on survival, disease-free survival,
long-term complications of treatment, and response to retreatment. At a
median follow-up time of 82 months (range, 54 to 104 months), 23 of 24
patients remain alive. One patient has died of recurrent disease refractory
to treatment. Of the remaining 23 patients, 11 have relapsed at a median
time of 30 months (range, 7 to 80 months) after treatment completion. Of
these 11 patients, 7 have been retreated with dCF or
2'-chlorodeoxyadenosine (2-CdA), including one patient that was retreated
twice. All seven patients have responded, with five patients achieving
second complete remission. Two patients have had normalization of blood
cell counts, but repeat bone marrows have not been performed. No serious
infections have been seen in dCF-treated patients during follow-up. One
case of Hodgkin's disease and three cases of skin malignancies have
developed in these 24 patients. From initiation of treatment, survival is
93 months (range, 63 to 116 months). We concluded that dCF significantly
prolongs the survival of patients with advanced hairy cell leukemia without
resultant long-term complications. It is too early to predict if this
therapy will be curative for the patients still in remission.
Volume 84,
Issue 12,
pp. 4061-4063,
12/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hisada, B. E. Chen, E. S. Jaffe, and L. B. Travis
Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia: A Population-Based Study
J Natl Cancer Inst,
February 7, 2007;
99(3):
215 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Goodman, C. Burian, J. A. Koziol, and A. Saven
Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine
J. Clin. Oncol.,
March 1, 2003;
21(5):
891 - 896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, P. L. Zinzani, A. Frassoldati, M. Vinceti, A. Mode, L. Annino, T. Chisesi, G. Pagnucco, R. Invernizzi, M. Spriano, et al.
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up
J. Clin. Oncol.,
February 1, 2002;
20(3):
638 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. W. Flinn, K. J. Kopecky, M. K. Foucar, D. Head, J. M. Bennett, R. Hutchison, W. Corbett, P. Cassileth, T. Habermann, H. Golomb, et al.
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin
Blood,
November 1, 2000;
96(9):
2981 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, S. Pilat, and M. Duvic
Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations
J. Clin. Oncol.,
October 1, 1999;
17(10):
3117 - 3121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Iwata and C. Morimoto
CD26/Dipeptidyl Peptidase IV in Context: the Different Roles of a Multifunctional Ectoenzyme in Malignant Transformation
J. Exp. Med.,
August 2, 1999;
190(3):
301 - 306.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, D. A. Vena, J. Barrett, and B. Freidlin
Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias
J. Clin. Oncol.,
August 1, 1999;
17(8):
2454 - 2454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. Hakimian, K. J. Kopecky, S. Wheaton, E. Wollins, K. Foucar, P. A. Cassileth, T. Habermann, M. Grever, J. M. Rowe, et al.
Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2'-Deoxycoformycin and Prediction of Early Relapse
Clin. Cancer Res.,
July 1, 1999;
5(7):
1665 - 1670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. A. Koziol, and L. D. Piro
Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Blood,
September 15, 1998;
92(6):
1918 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Au, R. J. Klasa, R. Gallagher, N. Le, R. D. Gascoyne, and J. M. Connors
Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience
Blood,
August 15, 1998;
92(4):
1160 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lauria, M. Bocchia, G. Marotta, D. Raspadori, P. Zinzani, and D. Rondelli
Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications
Blood,
March 1, 1997;
89(5):
1838 - 1839.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
